NCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
Clinical Trials
67 trialsNCT05613088 2025-10-20
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT05567601 2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT00170573 2024-12-16
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Phase 2 Completed
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT03596281 2024-10-18
PEMBOV
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT03598270 2024-08-30
ANITA
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Completed
NCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT03719326 2024-05-24
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Arcus Biosciences, Inc.
Phase 1 Completed
NCT01705158 2023-09-06
MYCA
ARCAGY/ GINECO GROUP
Phase 1/2 Completed
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT03639246 2023-02-13
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Aravive, Inc.
Phase 1 Completed
NCT03161132 2023-01-27
ROLANDO
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Completed
NCT02431559 2022-10-10
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02865811 2022-09-13
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01673217 2022-08-01
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT00976911 2022-06-21
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01379989 2022-02-09
INOVATYON
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT02903004 2021-08-25
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Completed
NCT03480750 2020-11-10
Trientine
National Cheng-Kung University Hospital
Phase 1/2 Completed
NCT02631876 2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3 Completed
NCT02421588 2020-04-03
CORAIL
PharmaMar
Phase 3 Completed
NCT02394015 2020-03-27
RETRO-ROC
Grupo Español de Investigación en Cáncer de Ovario
Completed
NCT00628251 2019-12-05
ICEBERG 3
AstraZeneca
Phase 2 Completed
NCT02751918 2019-11-22
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Bayer
Phase 1 Completed
NCT00846612 2019-09-30
Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
NYU Langone Health
Phase 1 Completed
NCT00913835 2019-09-26
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01666444 2019-09-26
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Celgene
Phase 2 Completed
NCT01459380 2019-07-22
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01281514 2019-07-11
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
Fox Chase Cancer Center
Phase 1 Completed
NCT01846611 2019-04-01
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT01489371 2019-03-12
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 1 Completed
NCT03562533 2019-02-28
Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer
Konkuk University Medical Center
Completed
NCT03804866 2019-01-15
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
AGC Biologics S.p.A.
Phase 2 Completed
NCT03367182 2019-01-11
REBECA
Yonsei University
Completed
NCT01358071 2018-09-27
NGR018
AGC Biologics S.p.A.
Phase 2 Completed
NCT01113957 2018-06-06
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
AbbVie
Phase 2 Completed
NCT01145430 2017-12-22
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00659178 2017-07-21
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00727961 2017-06-08
A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00780039 2017-05-15
A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00523380 2017-03-01
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
Novo Nordisk A/S
Phase 2 Completed
NCT02262455 2017-02-13
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Phase 1 Completed
NCT02081495 2016-11-11
A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT02728622 2016-04-05
Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Completed
NCT00182767 2016-03-10
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01637532 2016-01-26
PITCH
Leiden University Medical Center
Phase 1/2 Completed